ChihHsien Lo - ScinoPharm Taiwan Chairman of the Board, Chief Strategy Officer
| 1789 Stock | TWD 22.50 0.15 0.67% |
Chairman
Mr. Alex ChihHsien Lo was serving as Chairman of the Board and Chief Strategy Officer in ScinoPharm Taiwan, Ltd. since August 18, 2017. He holds a MBA from University of California, Los Angeles, the United States. He is also Chairman of the Board and General Manager in PRESCO Netmarketing Inc, Chairman of the Board in UniPresident Enterprises Corporationration President Chain Store Corporationration President Natural Industrial Corporationration Ton Yi Industrial Corporationration TTET Union Corporationration Prince Housing Dvlpmt Corporationration ChengShi Invt Holding Co, Time Square Intl Co Ltd, DonFung Corporationration Prince Corporationration Prince Real Estate Co Ltd, Kai Yu Invt Co, President Packaging Corporationration President Intl Dvlpmt Corporationration Tong Yu Invt Corporationration President Property Corporationration UniPresident Cold Chain Corporationration UniPresident Dream Parks Corporationration UniOAO Travel Service Corporationration Kai Nan Invt Co Ltd, President Century Corporationration UniPresident Co Ltd, UniPresident Ltd, ZhangliaGang President Nissan Food Co Ltd, UniPresident Corporationration UniPresident China Holdings Ltd, President Enterprises Invt Co Ltd and Tong Ren Corporationration Vice Chairman of the Board in President Nisshin Corporationration as well as Director in President Baseball Team Corporationration Nanlien Intl Corporationration Tone Sang Const Corporationration Retail Support Intl Corporationration Presicarre Corporationration President Fair Dvlpmt Corporationration President tarbucks Coffee Corporationration UniPresident Organics Corporationration PK VC Corporationration UniPresident Glass Industrial Co Ltd, Kuang Chuan Dairy Co Ltd, Kuang Chuan Foods Co Ltd, UniPresident Dvlpmt Corporationration Tait Marketing Dist Co Ltd, Weilih Food Corporationration Keng Ting Enterprises Co Ltd, Prince Property Management Consulting Co, Kao Chyuan Inv. Corporationration PCS Holdings Ltd, PCS Holdings Ltd, Cayman President Holdings Ltd, Kai Yu Invt Co Ltd, President Packing Holdings Ltd, UniPresident Southeast Asia Holdings Ltd, PT since 2017.
| Age | 66 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 886 6 505 2888 |
| Web | https://www.scinopharm.com |
ScinoPharm Taiwan Management Efficiency
The company has return on total asset (ROA) of 0.0184 % which means that it generated a profit of $0.0184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0295 %, meaning that it generated $0.0295 on every $100 dollars invested by stockholders. ScinoPharm Taiwan's management efficiency ratios could be used to measure how well ScinoPharm Taiwan manages its routine affairs as well as how well it operates its assets and liabilities.ScinoPharm Taiwan has accumulated 2.29 B in total debt with debt to equity ratio (D/E) of 21.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ScinoPharm Taiwan has a current ratio of 3.31, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ScinoPharm Taiwan until it has trouble settling it off, either with new capital or with free cash flow. So, ScinoPharm Taiwan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ScinoPharm Taiwan sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ScinoPharm to invest in growth at high rates of return. When we think about ScinoPharm Taiwan's use of debt, we should always consider it together with cash and equity.
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan. SCINOPHARM TAIWAN operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange. ScinoPharm Taiwan (1789) is traded on Taiwan Stock Exchange in Taiwan and employs 47 people. Management Performance
| Return On Equity | 0.0295 | |||
| Return On Asset | 0.0184 |
ScinoPharm Taiwan Leadership Team
Elected by the shareholders, the ScinoPharm Taiwan's board of directors comprises two types of representatives: ScinoPharm Taiwan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ScinoPharm. The board's role is to monitor ScinoPharm Taiwan's management team and ensure that shareholders' interests are well served. ScinoPharm Taiwan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ScinoPharm Taiwan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shun Lin, Director Devel | ||
| ChihHui Lin, Sr Off | ||
| ChihHsien Lo, Chairman of the Board, Chief Strategy Officer | ||
| LiAn Lu, Deputy General Manager-Administrative Management Center | ||
| Jason Chen, Director Admin | ||
| LingHsiao Lien, VicePres Operations | ||
| BS MS, VP Officer | ||
| LiChiao Chemistry, VP Officer |
ScinoPharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ScinoPharm Taiwan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0295 | |||
| Return On Asset | 0.0184 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 16.28 B | |||
| Shares Outstanding | 790.74 M | |||
| Shares Owned By Insiders | 58.97 % | |||
| Shares Owned By Institutions | 16.86 % | |||
| Price To Earning | 51.64 X | |||
| Price To Book | 1.92 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.